These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8388609)

  • 1. Monitoring tumor cell kinetics in patients receiving chemotherapy for small cell lung cancer.
    Kuo SH; Luh KT
    Acta Cytol; 1993; 37(3):353-7. PubMed ID: 8388609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced cell cycle perturbation in chemotherapy of patients with non-small cell lung cancer.
    Kuo SH; Luh KT
    Cytopathology; 1990; 1(4):211-6. PubMed ID: 1966265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR; Fuks JZ; Ettinger DS; Chang AY; Ruckdeschel JC; Phan SC; Blum RH
    Cancer J Sci Am; 2000; 6(1):34-9. PubMed ID: 10696737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.
    Brennan J; O'Connor T; Makuch RW; Simmons AM; Russell E; Linnoila RI; Phelps RM; Gazdar AF; Ihde DC; Johnson BE
    Cancer Res; 1991 Mar; 51(6):1708-12. PubMed ID: 1847842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of small cell lung cancer].
    Komiya T; Takada M
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1116-23. PubMed ID: 8751797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
    J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
    Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
    Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
    Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
    Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
    Gandhi L; Harding MW; Neubauer M; Langer CJ; Moore M; Ross HJ; Johnson BE; Lynch TJ
    Cancer; 2007 Mar; 109(5):924-32. PubMed ID: 17285598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy for small cell lung cancer.
    Sufarlan AW; Zainudin BM
    Med J Malaysia; 1993 Jun; 48(2):166-70. PubMed ID: 8394502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer.
    Behera D; Jindal SK; Sharma SC
    Indian J Chest Dis Allied Sci; 1995; 37(1):15-9. PubMed ID: 16892733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of small cell lung carcinoma associated with pneumoconiosis who responded well to the over twenty chemotherapy treatments, resulting in prolonged survival].
    Sassa K; Mizushima Y; Yoshida Y; Shinoda K; Kobayashi M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):609-12. PubMed ID: 9087297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery for cure of small cell bronchial carcinoma (SCLC) at early stages and postoperative combined modality treatment.
    Karrer K; Denck H; Karnicka-Mlodkowska H; Drings P; Erzen J; Salzer GM;
    J Chemother; 1989 Jul; 1(4 Suppl):1207-8. PubMed ID: 16312836
    [No Abstract]   [Full Text] [Related]  

  • 18. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relationship between morphological manifestations and cell kinetic changes of human lung cancer cells after exposure to chemotherapeutic agents].
    Ito M
    Hokkaido Igaku Zasshi; 1986 Sep; 61(5):718-36. PubMed ID: 2430876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.